The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
Lothar Mueller
No relevant relationships to disclose
Peter J. Goebell
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
A. Lueck
No relevant relationships to disclose
Friedrich Overkamp
No relevant relationships to disclose
Michele Vogt
No relevant relationships to disclose
Norbert Marschner
No relevant relationships to disclose